RankAlpha logo
Back to Rankings

XNCR

XencorF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Primary-source updates support multiple dated pipeline milestones, and management maintained year-end cash guidance and runway into mid-2028 despite the royalty dispute. If XmAb819 data or autoimmune milestones de-risk the pipeline, the current price could be too discounting for a company with several shots on goal.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -1.4.
What can break
Alexion told Xencor it does not owe additional U.S. Ultomiris royalties and does not intend to make future U.S. payments, creating a live royalty-dispute overhang.
Momentum
23
Value
41
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $11.50 · Bull $16.00 · Bear $8.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $29.82
Why
Momentum23 · Δ7d -3.6
Value41 · Δ7d +0.1
Sentiment54 · Δ7d -1.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
23
34% active weight
Current posture
7d trendFlat
Δ7d
-3.6
Δ21d
-23.1
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
54
33% active weight
Current posture
7d trendSoftening
Δ7d
-1.4
Δ21d
-50.6
Why this grade

Composite grade F. Momentum 22.8 / Value 41.1 / Sentiment 53.7

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$874.87M
Beta
0.99
Shares Out
71.41M
P/E (TTM) · Derived
-9.9
P/S (TTM)
6.09
P/FCF (TTM) · Derived
-6.30
Rev YoY
+18.0%
EPS YoY
+89.1%
Gross Margin
-
Op Margin
-76.6%
Net Debt
-$334.17M
Current Ratio
5.99
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology